Per the 10K, ARRY was awarded a number of shares of preferred stock from Loxo equal to 19.9% interest in Loxo for the licensing rights to Loxo-101. When Loxo went public, those preferred shares were converted to 1.6 million common shares and promptly sold by ARRY for $20.8 million. So basically, ARRY got $21 million for their equity position, they receive $6-7 million a year from Loxo to pay for FTEs related to drug development, they'll get milestones in the single-digit millions and should Loxo bring Loxo-101 to market, ARRY will receive mid-single-digit royalties. Not a good deal.
You're counting that as news? Go play in traffic and leave this message board to the grownups.
On another note, I'd about given up on the drugs that ARRY partnered on with Aslan and VentiRX because of a lack of news. It was nice seeing VentiRX announce a combo trial involving ARRY's TLR and a big pharma company's checkpoint inhibitor last week. Also very cool to see all the updates on the Aslan website and check out the five combo trials they're doing with ARRY's ASLAN001.